| 1 |
Sardh E, Harper P. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria. J Intern Med 2022;291:593-610. [PMID: 35067977 DOI: 10.1111/joim.13443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 2 |
Vassiliou D, Sardh E. Acute hepatic porphyria and maternal health: Clinical and biochemical follow-up of 44 pregnancies. J Intern Med 2022;291:81-94. [PMID: 34411356 DOI: 10.1111/joim.13376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Huang L, Zhang L, Li W, Li S, Wen J, Li H, Liu Z. Advances in Development of mRNA-Based Therapeutics. Curr Top Microbiol Immunol 2022;440:147-66. [PMID: 32683507 DOI: 10.1007/82_2020_222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 4 |
Ventura P, Bonkovsky HL, Gouya L, Aguilera-Peiró P, Montgomery Bissell D, Stein PE, Balwani M, Anderson DKE, Parker C, Kuter DJ, Monroy S, Oh J, Ritchie B, Ko JJ, Hua Z, Sweetser MT, Sardh E; ENVISION Investigators. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int 2022;42:161-72. [PMID: 34717041 DOI: 10.1111/liv.15090] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 5 |
Sharma R, Singh A, Chaturvedi A. Acute intermittent porphyria presenting with posterior reversible encephalopathy syndrome: A case report. J Pediatr Crit Care 2021;8:243. [DOI: 10.4103/jpcc.jpcc_10_21] [Reference Citation Analysis]
|
| 6 |
Knotek M, Novak R, Jaklin-Kekez A, Mrzljak A. Combined liver-kidney transplantation for rare diseases. World J Hepatol 2020;12:722-37. [PMID: 33200012 DOI: 10.4254/wjh.v12.i10.722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 7 |
Jiang L, Berraondo P, Jericó D, Guey LT, Sampedro A, Frassetto A, Benenato KE, Burke K, Santamaría E, Alegre M, Pejenaute Á, Kalariya M, Butcher W, Park JS, Zhu X, Sabnis S, Kumarasinghe ES, Salerno T, Kenney M, Lukacs CM, Ávila MA, Martini PGV, Fontanellas A. Systemic messenger RNA as an etiological treatment for acute intermittent porphyria. Nat Med 2018;24:1899-909. [PMID: 30297912 DOI: 10.1038/s41591-018-0199-z] [Cited by in Crossref: 90] [Cited by in F6Publishing: 93] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 8 |
Stein PE, Badminton MN, Rees DC. Update review of the acute porphyrias. Br J Haematol 2017;176:527-38. [PMID: 27982422 DOI: 10.1111/bjh.14459] [Cited by in Crossref: 83] [Cited by in F6Publishing: 92] [Article Influence: 11.9] [Reference Citation Analysis]
|
| 9 |
Fontanellas A, Ávila MA, Berraondo P. Emerging therapies for acute intermittent porphyria. Expert Rev Mol Med 2016;18:e17. [PMID: 27804912 DOI: 10.1017/erm.2016.18] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 10 |
Bonnefoy Mirralles AM, Torres-Castro R, Ovalle Guzman C. A Comprehensive Rehabilitation Program and Follow-up Assessment for Acute Intermittent Porphyria. Am J Phys Med Rehabil 2017;96:e85-8. [PMID: 27584135 DOI: 10.1097/PHM.0000000000000590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 11 |
Ahangari A, Bäckström T, Innala E, Andersson C, Turkmen S. Acute intermittent porphyria symptoms during the menstrual cycle. Intern Med J. 2015;45:725-731. [PMID: 25871503 DOI: 10.1111/imj.12784] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 12 |
Lourenço CM, Anderson KE. Disorders of Haem Biosynthesis. Inborn Metabolic Diseases 2016. [DOI: 10.1007/978-3-662-49771-5_36] [Reference Citation Analysis]
|
